TELIX Pharmaceuticals Ltd Cash Flow Reinvestment Rate
TELIX Pharmaceuticals Ltd cash flow reinvestment rate. TELIX Pharmaceuticals Ltd (TLX) has a Cash Flow Reinvestment Rate of 0.36x as of June 2025, reinvesting AU$10.13 Million (capex AU$10.13 Million ) from operating cash flow of AU$27.98 Million. See TLX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of TELIX Pharmaceuticals Ltd (2020–2024)
Cash flow reinvestment rate of TELIX Pharmaceuticals Ltd from 2020 to 2024. Historical reinvestment intensity for TELIX Pharmaceuticals Ltd across 3 annual periods. Explore cash flow to debt ratio of TELIX Pharmaceuticals Ltd to assess how comfortably operating cash covers total debt obligations.
TELIX Pharmaceuticals Ltd Cash Flow Reinvestment Rate by Year (2020–2024)
TELIX Pharmaceuticals Ltd cash flow reinvestment rate by year from 2020 to 2024. Year-by-year capital reinvestment analysis for TELIX Pharmaceuticals Ltd. For the full cash flow conversion analysis, see TLX operating cash flow.
| Year | Reinvestment Rate | Total Reinvested (AUD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 3.93x | AU$169.21 Million | AU$43.03 Million | AU$34.03 Million | ▲ +158.9% |
| 2023 | 1.52x | AU$36.28 Million | AU$23.88 Million | AU$10.79 Million | ▲ +110.7% |
| 2020 | 0.72x | AU$1.41 Million | AU$1.96 Million | AU$322.00K | — |